OSI Closes Lid On Eyetech Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite last-minute blink surrounding potential Macugen competition from Genentech’s Lucentis, OSI announces completion of the $935 mil. merger.
You may also be interested in...
Valeant Adds Eyetech’s Macugen To Ophthalmic Portfolio
The acquisitive Canadian specialty pharma’s latest deal is a relatively small one, giving it a wet AMD treatment that lags behind Lucentis and other newcomers.
Archemix Outlicenses Aptamers To Ophthotech
Ophthotech, a new firm formed by several ex-Eyetech managers, will develop anti-C5 compounds as candidates to treat age-related macular degeneration.
Archemix Outlicenses Aptamers To Ophthotech
Ophthotech, a new firm formed by several ex-Eyetech managers, will develop anti-C5 compounds as candidates to treat age-related macular degeneration.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: